Kelly Fitzgerald, Md

This study tests a drug called zanzalintinib, combined with a bone-strengthening agent, in 20 people with advanced clear cell kidney cancer that has spread to the bones. Participants must have already tried 1-3 prior treatments, including immunotherapy. The goal is to see if the …